Not only is PD-1 highly expressed in tumor-infiltrating lymphocytes (TILs), but PD-L1 is also upregulated in tumor cells in many different cancer types, which has led to the design of anti-PD-1 therapies to overcome this immunosuppressed environment [51]. Here, PDCD1 is linked to cancer.